Davis To Shepherd Merck & Co. Toward The Post-Keytruda Era, As Frazier Exits
Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.
You may also be interested in...
Longtime R&D leader Roy Baynes is leaving Merck to become chief medical officer at the biotech start-up helmed by Merck's former R&D chief Roger Perlmutter.
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.